Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 41

Results For "discovery"

441 News Found

Junk food and low physical activity leading to diabetes: ASSOCHAM report
News | November 15, 2021

Junk food and low physical activity leading to diabetes: ASSOCHAM report

Diabetes has the highest prevalence and comorbidities among all NCD’s in India and it is mostly found among people in the south and east India


Jubilant Biosys expands Chemistry Innovation Research Centre
Supply Chain | November 12, 2021

Jubilant Biosys expands Chemistry Innovation Research Centre

The centre has an initial capacity of 500 FTEs


Clarivate and BARDA collaborate to identify therapeutics that can be repurposed for medical countermeasures
Biotech | November 09, 2021

Clarivate and BARDA collaborate to identify therapeutics that can be repurposed for medical countermeasures

Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries


Moderna and Metagenomi partner to develop next-gen in vivo gene editing therapeutics
Biotech | November 03, 2021

Moderna and Metagenomi partner to develop next-gen in vivo gene editing therapeutics

The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies


Biocon Q2FY22 in line with estimates, better margins: ICICI Direct
News | October 25, 2021

Biocon Q2FY22 in line with estimates, better margins: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Syngene reports better than expected revenues, margin pressure in Q1FY22: ICICI Direct
News | October 25, 2021

Syngene reports better than expected revenues, margin pressure in Q1FY22: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Jubilant Pharmova consolidated PAT at Rs. 142.84 cr. in Q2FY22
News | October 22, 2021

Jubilant Pharmova consolidated PAT at Rs. 142.84 cr. in Q2FY22

The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment


Syngene revenue from operations up 17 per cent in Q2FY22
News | October 21, 2021

Syngene revenue from operations up 17 per cent in Q2FY22

The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations


Resilience and Harvard announce five-year R&D alliance
News | October 18, 2021

Resilience and Harvard announce five-year R&D alliance

First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders


Exelixis in-licenses second anti-cancer compound from Aurigene
Biotech | October 15, 2021

Exelixis in-licenses second anti-cancer compound from Aurigene

U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma